Search
Skip to Search Results- 2Veldhoen, Richard
- 1Aburahess, Salah
- 1Akuamoah Boateng, Maxwell
- 1Alqahtani,Hind M
- 1Bekele, Raie Taye
- 1Benesch, Matthew GK
-
Fall 2016
Breast cancer (BrCa) is the most common cancer and the leading cause of cancer-related deaths in women worldwide. Current therapies for BrCa are insufficient to cure metastatic disease and are often associated with debilitating side effects that severely deteriorate the quality of patients’...
-
Spring 2016
Tamoxifen is the accepted therapy for patients with estrogen receptor α (ERα)−positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital...
-
Spring 2012
In Canada, approximately 40% of the population will be diagnosed with cancer and 25% will die of this disease. In order to treat cancer more effectively, new prognostic and therapeutic targets need to be discovered. In breast cancer, the BH3 only protein BAD has been shown to correlate with...
-
Spring 2020
To ensure faithful cell division, entry into mitosis must be inhibited in cells with damage or under-replicated DNA. Wee1 and Myt1 are two partially redundant kinases that inhibit mitotic entry through the phosphorylation of the Cdk1/cyclin B complex. Cdk1 is an essential mitotic kinase that...
-
Spring 2021
The transcription factors FOXC1, FOXQ1, and FOXF2 (FOX cluster on chromosome 6) are members of the forkhead family that play a role in a plethora of biological processes during development and tumorigenesis. Emerging studies in the last decade have suggested a role of the FOX cluster in breast...
-
Quality of Life, Exercise Behaviour and Baseline Dietary Intake of Women Undergoing Neoadjuvant Chemotherapy in the DHA WIN Randomized Controlled Trial
DownloadSpring 2024
Breast cancer is the second most common cancer in Canada. It is estimated that one in eight Canadian women will be diagnosed with the disease in their lifetime. Neoadjuvant chemotherapy is often prescribed to improve surgical resection outcomes and reduce micrometastases. Achieving a pathological...
-
Fall 2011
Taxanes are used for the treatment of breast, ovarian, and lung cancer. Unfortunately, taxane based therapy—the current treatment for metastatic breast cancer—has substantial shortcomings including myelosupression, neurotoxicity, and frequently acquired resistance. Our present understanding of...
-
Fall 2011
Taxanes are used for the treatment of breast, ovarian, and lung cancer. Unfortunately, taxane based therapy—the current treatment for metastatic breast cancer—has substantial shortcomings including myelosupression, neurotoxicity, and frequently acquired resistance. Our present understanding of...
-
MOLECULAR AND PHENOTYPIC CHARACTERIZATION OF DISTINCT BREAST CANCER CELL SUBPOPULATIONS PURIFIED USING A SOX2 REGULATORY REGION 2 TRANSCRIPTION ACTIVITY REPORTER
DownloadFall 2015
Sex-determining Region Y-box 2 (Sox2) is a transcription factor integral to the maintenance of pluripotency in embryonic stem cells. In recent years, Sox2 expression has been detected and implicated in the pathogenesis of breast and other cancers. Clinically, Sox2 expression has been associated...
-
Living at-Risk for Hereditary Breast Cancer: The Experiences of at-Risk Unaffected Women Who Live in Families Where a BRCA Gene Mutation Could Not be Found
DownloadSpring 2016
Harmful mutations in the breast cancer 1 and 2 genes (BRCA1/2) and other breast cancer susceptibility genes are thought to account for less than 30% of familial breast cancer cases. Many affected women (those with a personal history of breast and/or ovarian cancer) who undergo BRCA1/2 genetic...